Savara (NASDAQ:SVRA) posted its quarterly earnings data on Wednesday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03), Morningstar.com reports.
Shares of SVRA traded up $0.95 on Thursday, reaching $10.77. The company’s stock had a trading volume of 114,155 shares, compared to its average volume of 190,424. The company has a current ratio of 10.30, a quick ratio of 10.30 and a debt-to-equity ratio of 0.16. The company has a market cap of $335.85 million, a price-to-earnings ratio of -6.12 and a beta of -0.06. Savara has a 12-month low of $8.41 and a 12-month high of $17.19.
In related news, CFO David L. Lowrance sold 18,480 shares of the firm’s stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $9.22, for a total value of $170,385.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 6.10% of the company’s stock.
SVRA has been the topic of a number of research reports. Canaccord Genuity set a $25.00 price objective on shares of Savara and gave the stock a “buy” rating in a report on Tuesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Savara in a report on Friday, August 10th. Zacks Investment Research raised shares of Savara from a “sell” rating to a “hold” rating in a report on Thursday, July 26th. Finally, BidaskClub downgraded shares of Savara from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $26.80.
COPYRIGHT VIOLATION NOTICE: “Savara (SVRA) Posts Earnings Results, Misses Expectations By $0.03 EPS” was posted by WKRB News and is owned by of WKRB News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.wkrb13.com/2018/11/09/savara-svra-posts-earnings-results-misses-expectations-by-0-03-eps.html.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Recommended Story: Understanding Stock Ratings
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.